Risk assessment of using off‐label morphine sulfate in a population‐based retrospective cohort of opioid‐dependent patients

Abstract

This first French comprehensive nationwide study reveals increasing overdose, death, bacterial infection, abuse and diversion risks when off-label MS is initiated as alternative to OST. These results question the relevance of prescribing MS as a safe opioid maintenance treatment, considering its health risk profile.